Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer--a feasibility study

Asian Pac J Cancer Prev. 2014;15(14):5909-16. doi: 10.7314/apjcp.2014.15.14.5909.


Human papillomavirus infection (HPV) and HPV related immune perturbation play important roles in the development of cervical cancer. Since mature dendritic cells (DCs) are potent antigen-presenting cells (APC), they could be primed by HPV antigens against cervical cancers. In this study we were able to generate, maintain and characterize, both phenotypically and functionally, patient specific dendritic cells in vitro. A randomized Phase I trial with three arms--saline control (arm I), unprimed mature DC (arm II) and autologous tumor lysate primed mature DC (arm III) and fourteen patients was conducted. According to WHO criteria, grade 0 or grade one toxicity was observed in three patients. One patient who received tumor lysate primed dendritic cells and later cis-platin chemotherapy showed a complete clinical response of her large metastatic disease and remained disease free for more than 72 months. Our findings indicate that DC vaccines hold promise as adjuvants for cervical cancer treatment and further studies to improve their efficacy need to be conducted.

Publication types

  • Clinical Trial, Phase I
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cancer Vaccines / immunology*
  • Cell- and Tissue-Based Therapy / methods*
  • Cisplatin / therapeutic use
  • Dendritic Cells / immunology
  • Dendritic Cells / transplantation*
  • Feasibility Studies
  • Female
  • Humans
  • Middle Aged
  • Papillomaviridae / immunology
  • Papillomavirus Infections / immunology
  • Papillomavirus Infections / virology
  • Uterine Cervical Neoplasms / immunology
  • Uterine Cervical Neoplasms / therapy*
  • Uterine Cervical Neoplasms / virology
  • Vaccination


  • Cancer Vaccines
  • Cisplatin